H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Neutral rating on Summit Therapeutics plc (NASDAQ: SMMT).The analyst commented: "HARMONi-2’s interim ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE